Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
PHVS · Why this verdict
Why Pharvaris (PHVS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pharvaris is a cash-burning clinical-stage biotech with a quality score of only 1.5 out of 10, but strong analyst conviction with 48% upside to targets and a momentum breakout pattern — the risk profile is speculative with 3 of the last 4 earnings misses.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With negative FCF, zero operating margin, and a quality score of 1.5 out of 10 — well below the 4.0 minimum threshold — Pharvaris is a cash-burning clinical biotech whose financial profile does not meet standard investment criteria. Quality breakdown | Quality score rises above 4.0 within 12 months as the company progresses toward commercialization and narrows its cash burn rate. | →Stable |
| CounterPre-revenue clinical biotechs are expected to burn cash; the current ratio of 5.0 indicates 5 years of operational runway which may be sufficient for clinical readouts to create value. | ||
Pharvaris has missed earnings expectations in 3 of the last 4 quarters with an average negative surprise of -4.0%, and the elevated put-to-call ratio of 2.64 suggests options market participants are positioned for further downside. Catalyst breakdown | Next earnings report in 57 days shows a positive surprise, and the put-to-call ratio falls below 1.5 within 6 months. | →Stable |
| CounterBiotech earnings misses often reflect non-cash charges or R&D timing rather than revenue failure; the one beat was +10.7%, suggesting the company can exceed expectations when clinical milestones align. | ||
Analysts project 48% upside from current levels with a price target of $40.48 against a current price of $31.54, and the sentiment score is 8.5 out of 10 with LLM news sentiment at +0.50. Sentiment breakdown | Stock price rises above $38.00 within 12 months as clinical trial progress validates the analyst thesis. | →Stable |
| CounterHigh analyst price targets for clinical biotechs often reflect binary event optionality rather than near-term intrinsic value; if a trial fails, targets collapse. | ||
The stock shows a golden cross pattern above all moving averages with RSI at 59, MACD bullish, and rising OBV — a momentum score of 6.5 out of 10 in a positive breakout configuration despite the weak fundamentals. Momentum breakdown | Momentum score remains above 5.5 and price holds above the 200-day moving average for 3 consecutive months. | →Stable |
| CounterTechnical breakouts in cash-burning biotechs can be driven by short-covering or event speculation rather than fundamental improvement, and the stock is above the max pain level of $22.50. | ||
With negative FCF, zero operating margin, and a quality score of 1.5 out of 10 — well below the 4.0 minimum threshold — Pharvaris is a cash-burning clinical biotech whose financial profile does not meet standard investment criteria.
→StableQuality breakdown
- Expectation
- Quality score rises above 4.0 within 12 months as the company progresses toward commercialization and narrows its cash burn rate.
CounterPre-revenue clinical biotechs are expected to burn cash; the current ratio of 5.0 indicates 5 years of operational runway which may be sufficient for clinical readouts to create value.
Pharvaris has missed earnings expectations in 3 of the last 4 quarters with an average negative surprise of -4.0%, and the elevated put-to-call ratio of 2.64 suggests options market participants are positioned for further downside.
→StableCatalyst breakdown
- Expectation
- Next earnings report in 57 days shows a positive surprise, and the put-to-call ratio falls below 1.5 within 6 months.
CounterBiotech earnings misses often reflect non-cash charges or R&D timing rather than revenue failure; the one beat was +10.7%, suggesting the company can exceed expectations when clinical milestones align.
Analysts project 48% upside from current levels with a price target of $40.48 against a current price of $31.54, and the sentiment score is 8.5 out of 10 with LLM news sentiment at +0.50.
→StableSentiment breakdown
- Expectation
- Stock price rises above $38.00 within 12 months as clinical trial progress validates the analyst thesis.
CounterHigh analyst price targets for clinical biotechs often reflect binary event optionality rather than near-term intrinsic value; if a trial fails, targets collapse.
The stock shows a golden cross pattern above all moving averages with RSI at 59, MACD bullish, and rising OBV — a momentum score of 6.5 out of 10 in a positive breakout configuration despite the weak fundamentals.
→StableMomentum breakdown
- Expectation
- Momentum score remains above 5.5 and price holds above the 200-day moving average for 3 consecutive months.
CounterTechnical breakouts in cash-burning biotechs can be driven by short-covering or event speculation rather than fundamental improvement, and the stock is above the max pain level of $22.50.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.5 |
| Price target | 8.8 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 33%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $7,163,170 (0.308% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.6 |
| growth rank | 5.0 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 0.4 |
| 52w position | 9.9 |
Risk (lower is worse)
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.4 |
| days to cover | 9.3 |
| volatility | 1.1 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| debt equity | 8.7 |
- ▸High IV: 86%
- ▸Above max pain $25
Catalyst
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.5 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.8>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:48d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (0)
none
Reward-to-Risk
1.05
Upside
+15.7%
Downside
15.0%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 66, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $2.3B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.6 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.1<1.5@spot.
The strongest dimensions are Sentiment at 7.6, Value at 7.5, and Momentum at 6.8; the weakest are Quality at 1.5, Catalyst at 2.6, and Insider at 3.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With negative FCF, zero operating margin, and a quality score of 1.5 out of 10 — well below the 4.0 minimum threshold — Pharvaris is a cash-burning clinical biotech whose financial profile does not meet standard investment criteria.
Trip ifCash burn rate increases by more than 20% quarter-over-quarter for 2 consecutive quarters, indicating deteriorating runway.
- P2Pharvaris has missed earnings expectations in 3 of the last 4 quarters with an average negative surprise of -4.0%, and the elevated put-to-call ratio of 2.64 suggests options market participants are positioned for further downside.
Trip ifEarnings miss consensus by more than 15% in the next quarterly report and put-to-call ratio rises above 3.5.
- P3Analysts project 48% upside from current levels with a price target of $40.48 against a current price of $31.54, and the sentiment score is 8.5 out of 10 with LLM news sentiment at +0.50.
Trip ifAnalyst consensus price target falls below $30.00, reducing implied upside to less than 0% from current levels.
- P4The stock shows a golden cross pattern above all moving averages with RSI at 59, MACD bullish, and rising OBV — a momentum score of 6.5 out of 10 in a positive breakout configuration despite the weak fundamentals.
Trip ifPrice drops below the 200-day moving average and momentum score falls below 4.5 for 2 consecutive weeks.